<H1> EDITORIAL SECTION </H1> |
<H1> Advisory Board </H1> |
<H1> KNOWLEDGE BANK </H1> |
<H1> TOP ARTICLES </H1> |
<H1> 1 </H1> |
<H1> 2 </H1> |
<H1> 3 </H1> |
<H1> 4 </H1> |
<H1> 5 </H1> |
<H1> press releasesRead more... </H1> |
<H1> EventsRead more... </H1> |
<H1> LATEST NEWSRead more... </H1> |
<H2> STRATEGY </H2> |
<H2> Strategic Partnerships in Biotech </H2> |
<H2> RESEARCH DEVELOPMENT </H2> |
<H2> unlock lab efficiencies and decision-making through a digital-first approach to lab transformation </H2> |
<H2> CLINICAL TRIALS </H2> |
<H2> Patient Recruitment in Asia </H2> |
<H2> MANUFACTURING </H2> |
<H2> Advanced Pharmaceutical Continuous Manufacturing of Liquid Dosage Forms </H2> |
<H2> Information Technology </H2> |
<H2> The Tsunami of Big Data for Pharma: Sink or Swim? </H2> |
<H2> Biopharma </H2> |
<H2> Greening the Pill: Pharmaceutical Companies Embrace Environmental Sustainability </H2> |
<H2> EXPERT Talk </H2> |
<H2> Bridging the Gap: Why CMC Expertise is Key to Scaling Biotech and CDMO Solutions </H2> |
<H2> Articles </H2> |
<H2> Navigating the EU Biosimilars Regulatory Terrain: A Comprehensive Overview </H2> |
<H2> Techno Trends </H2> |
<H2> Newly Engineered Cas9 Now Allows Isolated Gene-editing </H2> |
<H2> Projects </H2> |
<H2> Eli Lilly to upgrade Brazil production site with 15 million real ($6.4 million) </H2> |
<H2> Research Insights </H2> |
<H2> Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo </H2> |
<H2> whitepaper </H2> |
<H2> White Paper: Addressing The Pharmaceutical Quality Testing Bottleneck </H2> |
<H2> How to Optimize Batch Production in European Pharmaceutical Manufacturing? </H2> |
<H2> Emerging Therapies in Oncology: Advances beyond Traditional Chemotherapy </H2> |
<H2> Why is Pharmacogenetics and Pharmacogenomics Important? </H2> |
<H2> Pharma Patent Expirations: How European Generics are changing the Market </H2> |
<H2> Navigating the EU Biosimilars Regulatory Terrain: A Comprehensive Overview </H2> |
<H2> FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer </H2> |
<H2> LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer </H2> |
<H2> Ryvu Therapeutics to Present Preclinical Data on Synthetic Lethality at the 2025 AACR Annual Meeting </H2> |
<H2> Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome </H2> |
<H2> INTERPHEX 2025 </H2> |
<H2> RNA Connect </H2> |
<H2> Bio IT World Conference Expo 2025 </H2> |
<H2> 16th Strategic Alliance Management </H2> |
<H2> 6th Global Summit on Advances in Medicinal </H2> |
<H2> Pharmaceutica 2025 </H2> |
<H2> 15th World CB & CDx Summit Europe 2025 </H2> |
<H2> GMP PharmaCongress 2025 </H2> |
<H2> Dupixent (dupilumab) Becomes the First Biologic Medicine Approved in Japan for Chronic Obstructive Pulmonary Disease (COPD) </H2> |
<H2> Dupixent® (dupilumab) Receives Approval in Japan as the First Biologic Medicine for Chronic Obstructive Pulmonary Disease (COPD) </H2> |
<H2> Intellia Therapeutics Receives FDA RMAT Designation for Nexiguran Ziclumeran in Treating ATTR Amyloidosiswith Cardiomyopathy </H2> |
<H2> Ionis Expands Partnership with Sobi for Olezarsen Commercialisation Outside the U.S. </H2> |
<H2> Porosome Therapeutics Announces Major Breakthrough in Alzheimer’s Disease Research and Treatment </H2> |
<H2> Sermonix and Regor Collaborate to Enhance rCARD Platform for Identifying New Breast Cancer Treatments </H2> |
<H3> Strategies for Securing Pharma Manufacturing’s Fast-expanding Data Landscape </H3> |
<H3> The Pharmacovigilance IT Ecosystem </H3> |
<H3> Dissolution Profiles Comparison </H3> |
<H3> The Evolution of mRNA Therapeutics </H3> |
<H3> Orchestrating a Commercially Successful Cell and Gene Therapy </H3> |
<H3> Employing Advanced Therapy Medicinal Products in Oncology </H3> |
<H3> Why Clinical Trials Need Digital Endpoints </H3> |
<H3> Pharmaceutical - Digital Supply Chain Transformation </H3> |
<H3> The Role of AI and Machine Learning in Clinical Trials </H3> |
<H3> From Data to Decision </H3> |
<H3> Balancing Innovation and Risk Management in R&D </H3> |
<H3> DATA-DRIVEN MARKETING APPROACHES </H3> |
<H3> The Evolution of Medicine </H3> |
<H3> AI Revolutionizing Drug Discovery </H3> |
<H3> 01 - 03 </H3> |
<H3> 01 - 02 </H3> |
<H3> 02 - 03 </H3> |
<H3> 02 - 04 </H3> |
<H3> 03 - 05 </H3> |
<H3> 07 - 08 </H3> |
<H3> 08 - 10 </H3> |
<H3> 08 - 09 </H3> |
<H5> Kate Williamson </H5> |
<H5> Efficient batch production is critical in European pharmaceuticals. This guide outlines key strategies, including process mapping, technology integration, Quality by Design principles, data analytics,... </H5> |
<H5> Sarah Richards </H5> |
<H5> Chemotherapy as a method has been used together with radiation in treating cancer for many years but is associated with some drawbacks. Targeted therapy, immunotherapy, hormone therapy and precision m... </H5> |
<H5> Kate Williamson </H5> |
<H5> Pharmacogenetics and pharmacogenomics, exploring genetic influences on drug response, are pivotal in personalized medicine. By tailoring treatments to individual genetic makeup, these fields enhance d... </H5> |
<H5> Kate Williamson </H5> |
<H5> Due to recent patent liberalizations in Europe, new generics of essential drugs are available and at the same time affordable. This adaptive alteration is advantageous to both the health organizations... </H5> |
<H5> Kate Williamson </H5> |
<H5> This comprehensive overview explores the EU biosimilars regulatory landscape, including key differences from generic drugs, the multi-step approval process, regulatory guidelines, market trends, chall... </H5> |
<H5> Quick Links </H5> |
<H5> Get in Touch </H5> |
Social
Social Data
Cost and overhead previously rendered this semi-public form of communication unfeasible.
But advances in social networking technology from 2004-2010 has made broader concepts of sharing possible.